Kura Oncology Shares Are Trading Higher After the Company Received FDA Breakthrough Therapy Designation for Ziftomenib in NPM1-Mutant AML
在Kura Oncology获得美国食品药品管理局对NPM1突变体急性髓细胞白血病的Ziftomenib的突破性疗法认定后,该公司股价走高
Kura Oncology Shares Are Trading Higher After the Company Received FDA Breakthrough Therapy Designation for Ziftomenib in NPM1-Mutant AML
在Kura Oncology获得美国食品药品管理局对NPM1突变体急性髓细胞白血病的Ziftomenib的突破性疗法认定后,该公司股价走高
使用浏览器的分享功能,分享给你的好友吧